ELE + ketamine

**ELE + ketamine** refers to a combination of the investigational drug ELE (likely referring to eleclazine or a similar agent, though contextually unresolved in available data) with ketamine, a non-competitive **NMDA receptor antagonist** used primarily as an anesthetic and increasingly for treatment-resistant depression and refractory status epilepticus (SE). No specific clinical data identifies "ELE" definitively in combination with ketamine; searches primarily surface ketamine paired with diazepam for synergistic SE termination in animal models, where low-dose ketamine (10-50 mg/kg) with diazepam (20 mg/kg) rapidly controls prolonged cholinergic-induced SE refractory to either drug alone, via complementary GABA_A enhancement and NMDA blockade.[1] Ketamine's mechanism involves uncompetitive antagonism at NMDA receptor ion channels, preventing glutamate-induced excitotoxicity, with rapid antidepressant effects potentially via AMPA activation and BDNF upregulation; combination use aims to leverage synergy while mitigating ketamine's narrow therapeutic window and toxicity risks like respiratory arrest.